137 Cancer Medicines to Get Price Cuts From November 9: What Patients Need to Know

NEW DELHI, October 19, 2026: The cost of cancer treatment can place a heavy financial burden on patients and their families, with medicines, diagnostic tests, hospitalisation and repeated treatment sessions adding to household expenses. In a move aimed at easing this burden, the government has capped trade margins on 137 identified anti-cancer medicines, with revised prices scheduled to take effect from November 9, 2026.

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, announced the trade margin rationalisation measure on October 17. The government expects the maximum retail prices (MRPs) of the covered medicines to decline by up to 70%, depending on their existing price structures.

The decision is intended to curb excessive margins across the medicine distribution chain and improve access to cancer drugs. However, public health advocates have cautioned that lower medicine prices alone may not be enough to make cancer treatment affordable for every patient. 

Which Cancer Medicines Are Covered?

The new measure covers 137 identified non-scheduled anti-cancer drug formulations, including medicines used in different cancer treatments and supportive care.

The list includes drugs such as pembrolizumab, durvalumab, osimertinib, bevacizumab and denosumab, among others. These medicines have different indications and are prescribed according to the type of cancer, its stage and the patient’s clinical circumstances.

Some of the covered medicines are used in immunotherapy or targeted cancer treatment, while others serve different roles in oncology care.

The price revision does not mean that all cancer medicines available in India are covered. Patients should check whether their specific medicine and formulation appear on the notified list before expecting a price change. 

How Will the Price Cap Work?

Under the new order, trade margins on the identified medicines will be capped at 30% under the NPPA’s pricing mechanism. Manufacturers must submit revised price information to the authority within the prescribed period and ensure that applicable MRPs comply with the revised requirements.

The revised prices are scheduled to become effective on November 9, 2026. Manufacturers have also been directed to maintain existing production levels to help prevent interruptions in the availability of the covered medicines.

The government has introduced the measure under Paragraph 19 of the Drugs (Prices Control) Order, 2013. It builds on an earlier initiative launched in 2019, when trade margins were rationalised for 42 anti-cancer drugs. That exercise led to MRP reductions across 526 brands, with some prices falling by as much as 90%. 

Why This Matters for Cancer Patients

For people undergoing cancer treatment, medicine costs can influence how much they pay out of pocket and how difficult it is to sustain treatment alongside everyday living expenses.

Reducing the prices of covered medicines could offer financial relief to eligible patients, particularly those who need expensive drugs over multiple treatment cycles.

However, the actual benefit will vary. Not every patient uses a medicine included in the new list, and the reduction for an individual drug may be substantially smaller than the maximum projected cut.

Patients should also remember that cancer treatment is often multidisciplinary. The total cost may include consultations, pathology tests, imaging, surgery, radiotherapy, chemotherapy, supportive medicines and follow-up care. A reduction in the price of one drug will not automatically reduce these other expenses.

Public Health Advocates Call for Wider Reforms

Jan Swasthya Abhiyan India (JSA India), a public health advocacy group, has welcomed the decision but cautioned that the trade margin cap alone may not ensure affordable cancer care.

The group has called for broader medicine price controls, stronger monitoring and greater scrutiny of pricing information to ensure that the benefits reach patients. It has also emphasised that affordability should be assessed through the prices people actually pay at pharmacies and hospitals, along with changes in their overall out-of-pocket expenditure.

The concerns point to an important distinction: regulating distribution margins can help bring prices down, but it does not by itself resolve every issue affecting the cost of medicines and cancer treatment.

Effective implementation, transparent pricing and enforcement will be important in determining how much patients ultimately save. 

What Should Patients Do Before November 9?

Patients and caregivers can take the following steps to understand how the changes may affect them:

• • Check the medicine name and formulation: Confirm whether the prescribed drug is among the 137 covered formulations.

• • Ask for the revised MRP: From November 9, ask the dispensing pharmacy or hospital for the applicable revised price.

• • Keep bills and prescriptions: These can help patients compare prices and raise concerns if they believe they have been charged above the permitted MRP.

• • Ask about financial assistance: Hospitals, government schemes and eligible patient assistance programmes may provide additional support.

• • Do not alter treatment independently: Never stop, delay or substitute a prescribed cancer medicine solely because of its price. Discuss cost concerns and possible alternatives with the treating oncologist.

Patients who suspect overcharging can seek guidance from the relevant drug control authority or the NPPA.

The Road Ahead: From Lower Drug Prices to Affordable Cancer Care

The government’s decision represents a targeted attempt to address medicine costs through regulation of trade margins. Whether it produces meaningful financial relief will depend on the revised prices, the availability of medicines and compliance by manufacturers, distributors, pharmacies and hospitals.

For a more comprehensive public health response, medicine pricing measures need to work alongside early cancer detection, timely diagnosis, accessible treatment facilities, financial protection for families and support for patients throughout their treatment journey.

The Aarogyam Times Takeaway: The new price measure could provide relief to patients using the covered cancer medicines, but a reduction of up to 70% should not be interpreted as a guaranteed saving on every drug or on the total cost of cancer care. The real test will be whether patients see transparent, enforceable price reductions and can access the medicines they need without interruption.